ZINC GLUCONATE TRIHYDRATE

O.O.O.[Zn++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O

InChIKey=ZPQPBMFYUZNVPE-BMDZSJGYSA-L

InChI=1S/2C6H12O7.3H2O.Zn/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;/h2*2-5,7-11H,1H2,(H,12,13);3*1H2;/q;;;;;+2/p-2/t2*2-,3-,4+,5-;;;;/m11..../s1

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

Primary Target	Pharmacology	Condition	Potency
Streptococcus mutans 41	Inhibitor 8,504
respiratory burst 39	Activator 1,447
transformed cell apoptotic process 104	Activator 1,447
Methotrexate 38	Hydrolytic Enzyme 38
ultraviolet B-induced damage 38	Interacts 323
T cell mediated immunity 40	Activator 1,447
Zinc transporter ZIP1 38	Binding Agent 1,076
Zinc transporter ZIP2 38	Binding Agent 1,076

Condition	Modality	Highest Phase	Product
Unknown 2,596
Unknown 2,596
Unknown 2,596
Caries 43	Preventing	Basic research	Unknown
Ulcerative colitis 125	Primary	Approved 8,583	CORTROPHIN-ZINC
Zinc deficiency 39	Primary	Preclinical	Unknown
Acute myeloid leukemia 141	Primary	Basic research	Unknown
Breast cancer 432	Primary	Basic research	Unknown
Renal insufficiency 40	Secondary	Approved 8,583	VORAXAZE
Diaper dermatitis 38	Primary	Approved 8,583	VUSION
Poison Ivy dermatitis 38	Primary	Approved 8,583	ZINC OXIDE
Gastrointestinal disorders 94	Primary	Approved 8,583	ZINC SULFATE
Mucositis 39	Primary	Phase III 665	ZINC SULFATE
Dysgeusia 38	Primary	Phase III 665	ZINC SULFATE
Unknown 2,596

Show entries

Title	Date	PubMed
In vitro activity of zinc salts against human rhinoviruses.	1987 Apr	3038000
A medicated polycarboxylate cement to prevent complications in composite resin therapy.	1990 Jan	2404104
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.	1993 Aug	8404763
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.	1994 Dec	7899834
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.	1995 Nov 13	7488149